Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different doses and phases of the disease according to several treatment protocols, but we could not observe a consistent effect of peptide T ameliorating the disease. Lymph node cell proliferation and IL-4 and interferon-gamma production were also studied. We conclude that peptide T neither prevents nor ameliorates EAE in Lewis rats.
- Experimental autoimmune encephalomyelitis
- Lewis rat
- Multiple sclerosis
- Peptide T
Sáez-Torres, I., Espejo, C., Pérez, J. J., Acarín, N., Montalban, X., & Martínez-Cáceres, E. M. (2000). Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clinical and Experimental Immunology, 121, 151-156. https://doi.org/10.1046/j.1365-2249.2000.01259.x